Status:

COMPLETED

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Lead Sponsor:

Gynecologic Oncology Group

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Fallopian Tube Carcinoma

Infectious Disorder

Eligibility:

FEMALE

18+ years

Phase:

PHASE1

Brief Summary

This phase I trial is studying the side effects of giving carboplatin and paclitaxel together with pegfilgrastim in treating patients with stage III or stage IV ovarian epithelial, fallopian tube, pri...

Detailed Description

PRIMARY OBJECTIVES: I. Establish the feasibility of adjuvant dose-dense carboplatin and paclitaxel followed by pegfilgrastim, in terms of absence of grade 3 or 4 nonhematologic toxicities without maj...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Diagnosis of 1 of the following:
  • Primary peritoneal carcinoma
  • Fallopian tube carcinoma
  • Ovarian epithelial carcinoma
  • Carcinosarcoma
  • Stage III or IV disease
  • Previously untreated disease, except for mandatory prior surgery
  • No ovarian epithelial carcinoma of low malignant potential (i.e., borderline carcinomas)
  • GOG performance status 0-2
  • Absolute neutrophil count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 9.0 g/dL
  • Creatinine ≤ 1.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN
  • SGOT ≤ 2.5 times ULN
  • Alkaline phosphatase ≤ 2.5 times ULN
  • No peripheral neuropathy (sensory or motor) ≥ grade 2
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other invasive malignancies within the past 5 years except nonmelanoma skin cancer
  • No septicemia, severe infection, or acute hepatitis
  • No prior radiotherapy or chemotherapy
  • No prior cancer treatment that would contraindicate study treatment

Exclusion

    Key Trial Info

    Start Date :

    June 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    43 Patients enrolled

    Trial Details

    Trial ID

    NCT00352300

    Start Date

    June 1 2006

    Last Update

    December 31 2014

    Active Locations (11)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (11 locations)

    1

    University of California Medical Center At Irvine-Orange Campus

    Orange, California, United States, 92868

    2

    University of Iowa Hospitals and Clinics

    Iowa City, Iowa, United States, 52242

    3

    Cooper Hospital University Medical Center

    Camden, New Jersey, United States, 08103

    4

    New York University Langone Medical Center

    New York, New York, United States, 10016